<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1042</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2022-18-4-127-137</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>GYNECOLOGY. REVIEWS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ГИНЕКОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Malignant endometriosis-associated ovarian and extraovarian neoplasia (review of literature)</article-title><trans-title-group xml:lang="ru"><trans-title>Малигнизированные эндометриоз-ассоциированные овариальные и экстраовариальные неоплазии: обзор литературы</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0486-2404</contrib-id><name-alternatives><name xml:lang="en"><surname>Kotiv</surname><given-names>Kh. B.</given-names></name><name xml:lang="ru"><surname>Котив</surname><given-names>Х. Б.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Khristina B. Kotiv.</p><p>68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758; 41 Kirochnaya St., Saint Petersburg 191015</p></bio><bio xml:lang="ru"><p>Котив Христина Богдановна.</p><p>197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 191015 Санкт-Петербург, ул. Кирочная, 41</p></bio><email>kotiv.onc@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1719-7498</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorodnova</surname><given-names>T. V.</given-names></name><name xml:lang="ru"><surname>Городнова</surname><given-names>Т. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758</p></bio><bio xml:lang="ru"><p>197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1886-3993</contrib-id><name-alternatives><name xml:lang="en"><surname>Lavrinovich</surname><given-names>O. E.</given-names></name><name xml:lang="ru"><surname>Лавринович</surname><given-names>О. Е.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758</p></bio><bio xml:lang="ru"><p>197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6937-2740</contrib-id><name-alternatives><name xml:lang="en"><surname>Berlev</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Берлев</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>68 Leningradskaya St., Pesochnyy Settlement, Saint Petersburg 197758; 41 Kirochnaya St., Saint Petersburg 191015</p></bio><bio xml:lang="ru"><p>197758 Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68; 191015 Санкт-Петербург, ул. Кирочная, 41</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Petrov National Medical Research Oncology Center, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Петрова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-03" publication-format="electronic"><day>03</day><month>12</month><year>2022</year></pub-date><volume>18</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>127</fpage><lpage>137</lpage><history><date date-type="received" iso-8601-date="2022-08-03"><day>03</day><month>08</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-30"><day>30</day><month>04</month><year>2023</year></date></history><permissions><copyright-year>2022</copyright-year><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/1042">https://ojrs.abvpress.ru/ojrs/article/view/1042</self-uri><abstract xml:lang="en"><p>Malignant transformation of endometrioid heterotopias develops in 0.7-2.5 % of cases; 75 % of cases have an ovarian localisation and 25 % an extraovarian one. As it has been suggested that malignant endometriosis-associated neoplasia (MEAN) is developed in foci of atypical endometriosis. The review describes the mechanisms of carcinogenesis, the clinical and morphological features of the disease, and the principles of therapy. MEAN usually occur in younger women, are detected at stages I-II, and are mostly represented by clear cell and endometrioid carcinomas, but rare histological types have also been described. <italic>CTNNB1</italic>, <italic>PTEN</italic>, <italic>PIK3CA</italic> and <italic>ARID1A</italic> mutations are often detected in MEAN. The treatment of MEAN is not standardised, there are no prospective randomized trials assessing treatment. Patients with ovarian MEAN receive therapy similar to epithelial ovarian cancer. Patients with extraovarian localisation represent a subgroup that of patients that may require a personalised approach.</p></abstract><trans-abstract xml:lang="ru"><p>Злокачественная трансформация эндометриоидных гетеротопий развивается в 0,7-2,5 % случаев, из которых 75 % имеют овариальную локализацию, 25 % - экстраовариальную. Существует гипотеза о формировании малигнизированных эндометриоз-ассоциированных неоплазий (МЭАН) в очагах атипичного эндометриоза. В обзоре описаны механизмы канцерогенеза, клинико-морфологические особенности заболевания и принципы терапии. МЭАН обычно развиваются у молодых женщин, диагностируются на I-II стадии, в большинстве случаев представлены светлоклеточными и эндометриоидными карциномами, но также описаны редкие гистологические типы. мутации в генах <italic>CTNNB1</italic>, <italic>PTEN</italic>, <italic>PIK3CA</italic> и <italic>ARID1A</italic> часто выявляют при МЭАН. лечение МЭАН не стандартизовано, отсутствуют проспективные рандомизированные исследования. Пациентки с овариальной локализацией МЭАН получают терапию, соответствующую стандартам лечения рака яичников. больные с экстраовариальной локализацией представляют особую подгруппу пациенток, которым требуется персонализированный подход.</p></trans-abstract><kwd-group xml:lang="en"><kwd>endometriosis</kwd><kwd>ovarian cancer</kwd><kwd>endometriosis-associated cancer</kwd><kwd>endometriosis-associated tumours</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>эндометриоз</kwd><kwd>рак яичника</kwd><kwd>эндометриоз-ассоциированный рак</kwd><kwd>эндометриоз-ассоциированные опухоли</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was supported by the Russian Science Foundation grant No. 19-75-10062.</funding-statement><funding-statement xml:lang="ru">Работа выполнена при поддержке гранта РНФ № 19-75-10062.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Nezhat F., Datta M.S., Hanson V. et al. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril 2008;90(5):1559-70. DOI: 10.1016/jfertastert.2008.08.007</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Sayasneh A., Tsivos D., Crawford R. Endometriosis and ovarian cancer: a systematic review. ISRN Obstet Gynecol 2011;2011:140310. DOI: 10.5402/2011/140310</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Matias-Guiu X., Stewart C.J.R. Endometriosis-associated ovarian neoplasia. Pathology 2018;50(2):190-204. DOI: 10.1016/j.pathol.2017.10.006</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Van Gorp T., Amant F., Neven P. et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004;18(2): 349-71. DOI: 10.1016/j.bpobgyn.2003.03.001</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Gadducci A., Lanfredini N., Tana R. Novel insights on the malignant transformation of endometriosis into ovarian carcinoma. Gynecol Endocrinol 2014;30(9):612-7. DOI: 10.3109/09513590.2014.926325</mixed-citation></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Brinton L.A., Gridley G., Persson I. et al. Cancer risk after a hos-pital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997;176(3):572-9. DOI: 10.1016/s0002-9378(97)70550-7</mixed-citation><mixed-citation xml:lang="ru">Brinton L.A., Gridley G., Persson I. et al. Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 1997;176(3):572-9. DOI: 10.1016/s0002-9378(97)70550-7</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><mixed-citation>Brinton L.A., Lamb E.J., Moghissi K.S. et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004;82(2):405-14. DOI: 10.1016/j.fertnstert.2004.02.109</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Melin A., Sparen P., Persson I., Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006;21(5):1237-42. DOI: 10.1093/humrep/dei462</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Wilbur M.A., Shih I.M., Segars J.H., Fader A.N. Cancer Implications for Patients with Endometriosis. Semin Reprod Med 2017;35(1):110-6. DOI: 10.1055/s-0036-1597120</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kim H.S., Kim T.H., Chung H.H., Song Y.S. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. Br J Cancer 2014;110(7):1878-90. DOI: 10.1038/bjc.2014.29</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Dahiya A., Sebastian A., Thomas A. et al. Endometriosis and malignancy: The intriguing relationship. Int J Gynaecol Obstet 2021;155(1):72-8. DOI: 10.1002/ijgo.13585</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Krawczyk N., Banys-Paluchowski M., Schmidt D. et al. Endometriosis-associated Malignancy. Geburtshilfe Frauenheilkd 2016;76(2):176-81. DOI: 10.1055/s-0035-1558239</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Gandini S., Lazzeroni M., Peccatori F.A. et al. The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis. Crit Rev Oncol Hematol 2019;134:72-81. DOI: 10.1016/j.critrevonc.2018.12.009</mixed-citation></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Mogensen J.B., Kjar S.K., Mellemkj^r L., Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. Gynecol Oncol 2016;143(1):87-92. DOI: 10.1016/j.ygyno.2016.07.095</mixed-citation><mixed-citation xml:lang="ru">Mogensen J.B., Kjær S.K., Mellemkjær L., Jensen A. Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. Gynecol Oncol 2016;143(1):87-92. DOI: 10.1016/j.ygyno.2016.07.095</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><mixed-citation>Kok V.C., Tsai H.J., Su C.F., Lee C.K. The risks for ovarian, endometrial, breast, colorectal, and other cancers in women with newly diagnosed endometriosis or adenomyosis: a population-based study. Int J Gynecol Cancer 2015;25(6):968-76. DOI: 10.1097/IGC.0000000000000454</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Ulrich U., Buchweitz O., Greb R. et al. Interdisciplinary S2k Guidelines for the Diagnosis and Treatment of Endometriosis: Short Version - AWMF Registry No. 015-045, August 2013. Geburtshilfe Frauenheilkd 2013;73(9):890-8. DOI: 10.1055/s-0033-1350810</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Sampson J.A. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. Am J Pathol 1927;3(2):93-110.43.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Czernobilsky B., Morris W.J. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol 1979;53(3):318-23.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Schmidt D., Ulrich U. Endometriosis-related ovarian tumors. Pathologe 2014;35(4):348-54. DOI: 10.1007/s00292-014-1949-4</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Stamp J.P., Gilks C.B., Wesseling M. et al. BAF250a expression in atypical endometriosis and endometriosis-associated ovarian cancer. Int J Gynecol Cancer 2016;26(5):825-32. DOI: 10.1097/IGC.0000000000000698</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Varma R., Rollason T., Gupta J.K., Maher E.R. Endometriosis and the neoplastic process. Reproduction 2004;127(3):293-304. DOI: 10.1530/rep.1.00020</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Verceliini P., Vigano P., Buggio L. et al. Perimenopausal management of ovarian endometriosis and associated cancer risk: When is medical or surgical treatment indicated? Best Pract Res Clin Obstet Gynaecol 2018;51:151-68. DOI: 10.1016/j.bpobgyn.2018.01.017</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kurman R.J., Shih I.M. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol 2016;186(4):733-47. DOI: 10.1016/j.ajpath.2015.11.011</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Anglesio M.S., Papadopoulos N., Ayhan A. et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 2017;376(19):1835-48. DOI: 10.1056/NEJMoa1614814</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Li X., Zhang Y., Zhao L. et al. Whole-exome sequencing of endometriosis identifies frequent alterations in genes involved in cell adhesion and chromatin-remodeling complexes. Hum Mol Genet 2014;23(22):6008-21. DOI: 10.1093/hmg/ddu330</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Suda K., Nakaoka H., Yoshihara K. et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. Cell Rep 2018;24(7):1777-89. DOI: 10.1016/j.celrep.2018.07.037</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Kim J.J., Kurita T., Bulun S.E. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev 2013;34(1):130-62. DOI: 10.1210/er.2012-1043</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Dyson M.T., Kakinuma T., Pavone M.E. et al. Aberrant expression and localization of deoxyribonucleic acid methyltransferase 3B in endometriotic stromal cells. Fertil Steril 2015;104(4):953-963. e2. DOI: 10.1016/j.fertnstert.2015.06.046</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Bulun S.E., Monsivais D., Kakinuma T. et al. Molecular biology of endometriosis: from aromatase to genomic abnormalities. Semin Reprod Med 2015;33(3):220-4. DOI: 10.1055/s-0035-1554053</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Attia G.R., Zeitoun K., Edwards D. et al. Progesterone receptor isoform A but not B is expressed in endometriosis. J Clin Endocrinol Metab 2000;85(8):2897-902. DOI: 10.1210/jcem. 85.8.6739</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Biegel J.A., Busse T.M., Weissman B.E. SWI/SNF chromatin remodeling complexes and cancer. Am J Med Genet C Semin Med Genet 2014;166C(3):350-66. DOI: 10.1002/ajmg.c.31410</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Ayhan A., Mao T.L., Seckin T. et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 2012;22(8):1310-5. DOI: 10.1097/IGC.0b013e31826b5dcc</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Jones S., Wang T.L., Shih I.M. et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010;330(6001):228-31. DOI: 10.1126/science.1196333</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Mao T.L., Shih I.M. The roles of ARID1A in gynecologic cancer. J Gynecol Oncol 2013;24(4):376-81. DOI: 10.3802/jgo.2013.24.4.376</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Nishikimi K., Kiyokawa T., Tate S. et al. ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component. Histopathology 2015;67(6):866-71. DOI: 10.1111/his.12721</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Minlikeeva A.N., Freudenheim J.L., Eng K.H. et al. History of comorbidities and survival of ovarian cancer patients, results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2017;26(9):1470-73. DOI: 10.1158/1055-9965.EPI-17-0367</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Chandler R.L., Damrauer J.S., Raab J.R. et al. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. Nat Commun 2015;6:6118. DOI: 10.1038/ncomms7118</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Husseinzadeh N., Husseinzadeh H.D. mTOR inhibitors and their clinical application in cervical, endometrial and ovarian cancers: a critical review. Gynecol Oncol 2014;133(2):375-81. DOI: 10.1016/j.ygyno.2014.02.017</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Kuo K.T., Mao T.L., Jones S. et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009;174(5):1597-601. DOI: 10.2353/ajpath.2009.081000</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>De Melo A.C., Paulino E., Garces A.H.I. A review of mTOR Pathway inhibitors in gynecologic cancer. Oxid Med Cell Longev 2017;2017:4809751. DOI: 10.1155/2017/4809751</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Ishikawa M., Nakayama K., Nakamura K. et al. Affinity-purified DNA-based mutation profiles of endometriosis-related ovarian neoplasms in Japanese patients. Oncotarget 2018;9(19):14754-63. DOI: 10.18632/oncotarget.24546</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Sato N., Tsunoda H., Nishida M. et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000;60(24):7052-6.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Martínez-Salgado C., Rodríguez-Peña A.B., López-Novoa J.M. Involvement of small Ras GTPases and their effectors in chronic renal disease. Cell Mol Life Sci 2008;65(3):477-92. DOI: 10.1007/s00018-007-7260-2</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Králíčková M., Laganà A.S., Ghezzi F., Vetvicka V. Endometriosis and risk of ovarian cancer: what do we know? Arch Gynecol Obstet 2020;301(1):1-10. DOI: 10.1007/s00404-019-05358-8</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Farahani M.S., Shahbazi S., Moghaddam S.A., Mahdian R. Evaluation of KRAS gene expression and LCS6 variant in genomic and cell-free DNA of Iranian women with endometriosis. Reprod Sci 2015;22(6):679-84. DOI: 10.1177/1933719114556478</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Shahrabi-Farahani M., Shahbazi S., Mahdian R., Amini-Moghaddam S. K-Ras 4A transcript variant is up-regulated in eutopic endometrium of endometriosis patients during proliferative phase of menstrual cycle. Arch Gynecol Obstet 2015;292(1):225-9. DOI: 10.1007/s00404-014-3596-7</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Stewart C.J.R., Leung Y., Walsh M.D. et al. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol 2012;43(8):1177-83. DOI: 10.1016/j.humpath.2011.10.009</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>WHO Classification of Tumours of Female Reproductive Organs. 4th edn. Available at: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/WHO-Classification-Of-Tumours-Of-Female-Reproductive-Organs-2014</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Gras E., Catasus L., Arguelles R. et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 2001;92(11):2829-36. DOI: 10.1002/1097-0142(20011201)92:11&lt;2829::aid-cncr10094&gt;3.0.co;2-3</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Zhao C., Li S., Zhao M. et al. Prognostic values of DNA mismatch repair genes in ovarian cancer patients treated with platinum-based chemotherapy. Arch Gynecol Obstet 2018;297(1):153-9. DOI: 10.1007/s00404-017-4563-x</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Grassi T., Calcagno A., Marzinotto S. et al. Mismatch repair system in endometriotic tissue and eutopic endometrium of unaffected women. Int J Clin Exp Pathol 2015;8(2):1867-77.</mixed-citation></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Vasilets Yu.D., Arnotskaya N.E., Kudryavtsev I.A., Shevchenko E.V. Wnt signaling cascade in the pathogenesis of glioblastoma multiforme. Uspekhi molekularnoy onkologii = Advances in Molecular Oncology 2018;5(4):94-103. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Василец Ю.Д., Арноцкая Н.Е., Кудрявцев И.А., Шевченко Е.В. Wnt-сигнальный каскад в патогенезе мультиформной глиобластомы. Успехи молекулярной онкологии 2018;5(4):94-103.</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><mixed-citation>Maeda D., Shih I.M. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anat Pathol 2013;20(1):45-52. DOI: 10.1097/PAP.0b013e31827bc24d</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Shivanna S., Harrold I., Shashar M. et al. The c-Cbl ubiquitin ligase regulates nuclear в-catenin and angiogenesis by its tyrosine phosphorylation mediated through the Wnt signaling pathway. J Biol Chem 2015;290(20):12537-46. DOI: 10.1074/jbc.M114.616623</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Del Carmen M.G., Smith Sehdev A.E., Fader A.N. et al. Endometriosis-associated ovarian carcinoma: differential expression of vascular endothelial growth factor and estrogen/progesterone receptors. Cancer 2003;98(8):1658-63. DOI: 10.1002/cncr.11714</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Modesitt S.C., Tortolero-Luna G., Robinson J.B. et al. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002;100(4):788-95. DOI: 10.1016/s0029-7844(02)02149-x</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Benoit L., Arnould L., Cheynel N. et al. Malignant extraovarian endometriosis: a review. Eur J Surg Oncol 2006;32(1):6-11. DOI: 10.1016/j.ejso.2005.08.011</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Mostoufizadeh M., Scully R.E. Malignant tumors arising in endometriosis. Clin Obstet Gynecol 1980;23(3):951-63.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Ferrandina G., Palluzzi E., Fanfani F. et al. Endometriosis-associated clear cell carcinoma arising in caesarean section scar: a case report and review of the literature. World J Surg Oncol 2016;14(1):300. DOI: 10.1186/s12957-016-1054-7</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Han L., Zheng A., Wang H. Clear cell carcinoma arising in previous episiotomy scar: a case report and review of the literature. J Ovarian Res 2016;9:1. DOI: 10.1186/s13048-016-0211-5</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Tsuruga T., Hirata T., Akiyama I. et al. Mixed endometrioid and clear cell carcinoma arising from laparoscopic trocar site endometriosis. J Obstet Gynaecol Res 2019;45(8):1613-8. DOI: 10.1111/jog.14014</mixed-citation></ref><ref id="B62"><label>62.</label><citation-alternatives><mixed-citation xml:lang="en">Puchkov K.V., Popov A.A., Fedorov A.A., Fedotova I.S. Endometriosis-associated malignancies associated with deep infiltrative endometriosis: a review of the literature and clinical observations. Rossiyskiy vestnik akushera-ginekologa = Russian Bulletin of an Obstetrician-Gynecologist 2019;19(4):42-6. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Пучков К.В., Попов А.А., Федоров А.А., Федотова И.С. Эндометриоз-ассоциированные злокачественные опухоли, связанные с глубоким инфильтративным эндометриозом: обзор литературы и клинические наблюдения. Российский вестник акушера-гинеколога 2019;19(4):42-6.</mixed-citation></citation-alternatives></ref><ref id="B63"><label>63.</label><mixed-citation>Yantiss R.K., Clement P.B., Young R.H. Neoplastic and pre-neoplastic changes in gastrointestinal endometriosis: a study of 17 cases. Am J Surg Pathol 2000;24(4):513-24.</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Poon C., Rome R. Malignant extra-ovarian endometriosis: a case series of ten patients and review of the literature. Aust N Z J Obstet Gynaecol 2020;60(4):585-91. DOI: 10.1111/ajo.13178</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Tarumi Y., Mori T., Kusuki I. et al. Endometrioid adenocarcinoma arising from deep infiltrating endometriosis involving the bladder: a case report and review of the literature. Gynecol Oncol Rep 2015;13:68-70. DOI: 10.1016/j.gore.2015.07.003</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Kawate S., Takeyoshi I., Ikota H. et al. Endometrioid adenocarcinoma arising from endometriosis of the mesenterium of the sigmoid colon. Jpn J Clin Oncol 2005;35(3):154-7. DOI: 10.1093/jjco/hyi037</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Jones K.D., Owen E., Berresford A., Sutton C. Endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colon. Gynecol Oncol 2002;86(2):220-2. DOI: 10.1006/gyno.2002. 6643</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Palla V.V., Karaolanis G., Bliona T. et al. Endometrioid adenocarcinoma arising from colon endometriosis. SAGE Open Med Case Rep 2017;5:2050313X17745204. DOI: 10.1177/2050313X17745204</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Song L., Xing A., Li Q., Wang G. High-grade serous carcinoma resulting from rectal endometriosis and complicated with ovarian cancer. Front Oncol 2019;9:1252. DOI: 10.3389/fonc.2019.01252</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Pokieser W., Schmerker R., Kisser M. et al. Clear cell carcinoma arising in endometriosis of the rectum following progestin therapy. Pathol Res Pract 2002;198(2):121-4. DOI: 10.1078/0344-0338-00198</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Ulrich U., Rhiem K., Kaminski M. et al. Parametrial and rectovaginal adenocarcinoma arising from endometriosis. Int J Gynecol Cancer 2005;15(6):1206-9. DOI: 10.1111/j.1525-1438.2005.00184.x</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Gadducci A., Zannoni G.F. Endometriosis-associated extraovarian malignancies: a challenging question for the clinician and the pathologist. Anticancer Res 2020;40(5):2429-38. DOI: 10.21873/anticanres.14212</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Marchena-Gomez J., Conde-Martel A., Hemmersbach-Miller M., Alonso-Fernandez A. Metachronic malignant transformation of small bowel and rectal endometriosis in the same patient. World J Surg Oncol 2006;4(93).</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Barra F., Scala C., Biscaldi E. et al. Ureteral endometriosis: a systematic review of epidemiology, pathogenesis, diagnosis, treatment, risk of malignant transformation and fertility. Hum Re-prod Update 2018;24(6):710-30. DOI: 10.1093/humupd/dmy027</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Li M., Tan J., Zhang Y. et al. Assessing CT imaging features combined with CEA and CA125 levels to identify endometriosis-associated ovarian cancer. Abdom Radiol (NY) 2021;46(6):2367-75. DOI: 10.1007/s00261-020-02571-x</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Udomsinkul P., Triratanachart S., Oranratanaphan S. Risk factors for endometriotic-cyst associated ovarian cancer: A case controlled study. Taiwan J Obstet Gynecol 2020;59(2):269-74. DOI: 10.1016/j.tjog.2020.01.016</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Magalhaes J., Jammal M.P., Crispim P.C.A. et al. Role of biomarkers CA-125, CA-15.3 and CA-19.9 in the distinction between endometriomas and ovarian neoplasms. Biomarkers 2021;26(3):268-74. DOI: 10.1080/1354750X.2021.1885490</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Sarbazi F., Akbari E., Karimi A. et al. The clinical outcome of laparoscopic surgery for endometriosis on pain, ovarian reserve, and cancer antigen 125 (CA-125): a cohort study. Int J Fertil Steril 2021;15(4):275-9. DOI: 10.22074/IJFS.2021.137035.1018</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Huhtinen K., Suvitie P., Hiissa J. et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009;100(8):1315-9. DOI: 10.1038/sj.bjc.6605011</mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation>Yang B., Wang D., Chen H., Yang F. The association between endometriosis and survival outcomes of ovarian cancer: evidence-based on a meta-analysis. Niger J Clin Pract 2015;18(5):577-83. DOI: 10.4103/1119-3077.158941</mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation>De Leo A., Santini D., Ceccarelli C. et al. What is new on ovarian carcinoma: integrated morphologic and molecular analysis following the New 2020 World Health Organization Classification of Female Genital Tumors. Diagnostics (Basel) 2021;11(4):697. DOI: 10.3390/diagnostics11040697</mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation>Cannistra S.A. Cancer of the ovary. N Engl J Med 2004;351(24):2519-29. DOI: 10.1056/NEJMra041842</mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation>Mikhaleva L.M., Davydov A.I., Patsap O.I. et al. Malignant transformation and associated biomarkers of ovarian endometriosis: a narrative review. Adv Ther 2020;37(6):2580-603. DOI: 10.1007/s12325-020-01363-5</mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation>Wiegand K.C., Shah S.P., Al-Agha O.M. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010;363(16):1532-43. DOI: 10.1056/NEJMoa1008433</mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation>Cybulska P., Paula A., Tseng J. et al. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Gynecol Oncol 2019;154(3):516-23. DOI: 10.1016/j.ygyno.2019. 07.012</mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation>Lee C.H., Nucci M.R. Endometrial stromal sarcoma - the new genetic paradigm. Histopathology 2015;67(1):1-19. DOI: 10.1111/his.12594</mixed-citation></ref><ref id="B87"><label>87.</label><citation-alternatives><mixed-citation xml:lang="en">Tjulandina A.S., Kolomiets L.A., Nechushkina V.M. et al. Practical guidelines for drug treatment of ovarian cancer, primary peritoneal cancer, and cancer of the fallopian tubes. Prakticheskie rekomendatsii RUSSCO #3s2 = Practice Guidelines RUSSCO #3s2 2021;11(10):158-71. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Тюляндина А.С., Коломиец Л.А., Нечушкина В.М. и др. Практические рекомендации по лекарственному лечению рака яичников, первичного рака брюшины и рака маточных труб. Практические рекомендации RUSSCO #3s2 2021;11(10):158-71.</mixed-citation></citation-alternatives></ref><ref id="B88"><label>88.</label><mixed-citation>Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer. NCCN Guidelines v. 22. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&amp;id=1453</mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation>Jiang X., Yang J., Yu M. et al. Oncofertility in patients with stage I epithelial ovarian cancer: fertility-sparing surgery in young women of reproductive age. World J Surg Oncol 2017;15(1):154. DOI: 10.1186/s12957-017-1222-4</mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation>Yoshihara M., Kajiyama H., Tamauchi S. et al. Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis. J Gynecol Oncol 2019;30(6):e102. DOI: 10.3802/jgo.2019.30.e102</mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation>Nasioudis D., Mulugeta-Gordon L., McMinn E. et al. Fertility sparing surgery for patients with FIGO stage I clear cell ovarian carcinoma: a database analysis and systematic review of the literature. Int J Gynecol Cancer 2020;30(9):1372-7. DOI: 10.1136/ijgc-2020-001716</mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation>Mullen J., Kato S., Sicklick J.K., Kurzrock R. Targeting ARID1A mutations in cancer. Cancer Treat Rev 2021;100:102287. DOI: 10.1016/j.ctrv.2021.102287</mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation>Kuroda T., Ogiwara H., Sasaki M. et al. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. Gynecol Oncol 2019;155(3):489-98. DOI: 10.1016/j.ygyno.2019.10.002</mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation>Parra-Herran C., Lerner-Ellis J., Xu B. et al. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. Mod Pathol 2017;30(12):1748-59. DOI: 10.1038/modpathol.2017.81</mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation>Garda-Marin J.A., Pellicer-Franco E.M., Soria-Aledo V. et al. Malignant degeneration of rectal endometriosis. Rev Esp Enferm Dig 2015;107(12):761-3. DOI: 10.17235/reed.2015.3648/2014</mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation>Li N., Zhou W., Zhao L., Zhou J. Endometriosis-associated rectosigmoid cancer: a case report. BMC Cancer 2018;18(1):905. DOI: 10.1186/s12885-018-4797-4</mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation>Kondo E., Maki S., Nii M. et al. Long-term survival of a patient with malignant transformation of extragonadal endometriosis treated solely with chemotherapy: A case report. J Obstet Gynaecol Res 2018;44(12):2186-9. DOI: 10.1111/jog.13773</mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation>Loizzi V., Cormio G., Leone L. et al. A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis. J Obstet Gynaecol 2015;35(7):758-60. DOI: 10.3109/01443615.2015.1004526</mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation>Kim H.S., Kim M.A., Lee M. et al. Effect of endometriosis on the prognosis of ovarian clear cell carcinoma: a two-center cohort study and meta-analysis. Ann Surg Oncol 2015;22(8): 2738-45. DOI: 10.1245/s10434-014-4319-9</mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation>Paik E.S., Kim T.J., Choi C.H. et al. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol 2018;29(2):e18. DOI: 10.3802/jgo.2018.29.e18</mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation>Chen P., Zhang C.Y. Association between endometriosis and prognosis of ovarian cancer: an updated meta-analysis. Front Oncol 2022;12:732322. DOI: 10.3389/fonc.2022.732322</mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation>Bassiouny D., El-Baz M.A., Gamil T.M. et al. Endometriosis-associated ovarian cancer is a subset with a more favorable outcome and distinct clinical-pathologic characteristics. Int J Gynecol Pathol 2019;38(5):435-42. DOI: 10.1097/PGP.0000000000000533</mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation>Buys S.S., Partridge E., Black A. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305(22):2295-303. DOI: 10.1001/jama.2011.766</mixed-citation></ref></ref-list></back></article>
